Krischer J P, Ragab A H, Kun L, Kim T H, Laurent J P, Boyett J M, Cornell C J, Link M, Luthy A R, Camitta B
Pediatric Oncology Group, St. Louis, Missouri.
J Neurosurg. 1991 Jun;74(6):905-9. doi: 10.3171/jns.1991.74.6.0905.
In a randomized postoperative trial, adjuvant post-irradiation chemotherapy, consisting of nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP), was tested versus radiation therapy alone for newly diagnosed medulloblastoma in patients between 1 and 21 years of age. Patients treated with irradiation plus MOPP had a statistically significant increase in overall survival rate at 5 years posttreatment compared to patients treated with radiation therapy alone (74% vs. 56%; p = 0.06, adjusted for race and gender). Although the overall study failed to show a statistically significant advantage for irradiation plus MOPP in event-free survival (p = 0.18), statistical significance was attained in children 5 years of age or older (p = 0.05). More severe hematological toxicities occurred in the group with irradiation plus MOPP; however, this hematotoxicity appeared to be tolerable and acceptable. These results suggest that patients may benefit from combined irradiation and chemotherapy following surgery for medulloblastoma.
在一项随机术后试验中，对年龄在1至21岁的新诊断为髓母细胞瘤的患者，测试了由氮芥、长春新碱、丙卡巴肼和泼尼松组成的辅助放疗后化疗（MOPP方案）与单纯放疗的效果。与单纯接受放疗的患者相比，接受放疗加MOPP方案治疗的患者在治疗后5年的总生存率有统计学显著提高（74%对56%；经种族和性别调整后，p = 0.06）。尽管总体研究未能显示放疗加MOPP方案在无事件生存率方面有统计学显著优势（p = 0.18），但在5岁及以上儿童中达到了统计学显著性（p = 0.05）。放疗加MOPP方案组出现了更严重的血液学毒性；然而，这种血液毒性似乎是可耐受和可接受的。这些结果表明，髓母细胞瘤患者术后接受放疗和化疗联合治疗可能会受益。
